Diuretic Therapy in Severe Renal Insufficiency and Decompensated Heart Failure

Initial Dosage and Monitoring

• The European Society of Cardiology recommends an initial intravenous dose of 20-40 mg Furosemid (or equivalent) for patients with new-onset acute heart failure or acute decompensated chronic heart failure without prior oral diuretic therapy 1
• For patients already receiving chronic diuretic therapy, the initial intravenous dose should be at least equivalent to the oral dose 1
• The European Heart Journal suggests monitoring symptoms, urine output, renal function, and electrolytes regularly during the use of intravenous diuretics 1, 2

Dose Titration and Adjustment

• The dose should be titrated according to clinical response 3
• The dose should be reduced when fluid retention is controlled 4, 5, 6
• Serum potassium, sodium, and renal function should be monitored frequently (every 1-2 days) 4, 5, 6, 7

Management of Diuretic Resistance

• In cases of diuretic resistance, strategies such as increasing the dose and/or frequency of diuretic administration, using intravenous administration, and combining diuretic therapy (e.g., Furosemid + HCTZ, Furosemid + Spironolacton) may be effective 4, 6, 8
• The combination of Metolazon + Furosemid may also be effective in patients with renal failure 8
• Combining diuretic therapy with Dopamin or Dobutamin, reducing ACE inhibitor dose, and considering ultrafiltration or dialysis may also be considered 8

Special Considerations

• High bolus doses (>1 mg/kg) may carry the risk of reflexive vasokonstriction 4, 5, 6
• In acute coronary syndromes, diuretics should be used in low doses, and vasodilatory therapy should be preferred 4, 5, 6
• The causes of diuretic resistance (intravascular volume depletion, neurohormonal activation, decreased tubular secretion in renal failure, decreased renal perfusion) should be considered 4, 5, 6